IL-12 for expression in mammalian cell
View Patent ↗The present invention provides for nucleic acids improved for the expression of interleukin-12 (IL-12) in mammalian cells. The invention further provides for methods of expressing IL-12 in mammalian cells by transfecting the cell with a nucleic acid sequence encoding an improved IL-12 sequence.
1. A nucleic acid sequence pair encoding an interleukin-12 (IL-12) protein heterodimer, the nucleic acid sequence pair comprising an IL-12p35 nucleic acid sequence and an IL-12p40 nucleic acid sequence, wherein the IL-12p35 nucleic acid sequence has at least 95% sequence identity to SEQ ID NO:3, and the IL-12p40 nucleic acid sequence has at least 95% sequence identity to SEQ ID NO:6.
2. An expression vector comprising a nucleic acid sequence pair of claim 1 .
3. An isolated mammalian cell comprising a nucleic acid sequence pair of claim 1 .
4. An isolated mammalian cell comprising an expression vector of claim 2 .
5. A composition comprising the nucleic acid sequence pair of claim 1 and a pharmaceutically acceptable excipient.
6. A method of expressing IL-12 in a mammalian cell, the method comprising introducing a recombinant vector into a mammalian cell to express a nucleic acid sequence pair encoding an IL-12 protein heterodimer, the nucleic acid sequence pair comprising an IL-12p35 nucleic acid sequence and an IL-12p40 nucleic acid sequence, wherein the IL-12p35 nucleic acid sequence has at least 95% sequence identity to SEQ ID NO:3, and the IL-12p40 nucleic acid sequence has at least 95% sequence identity to SEQ ID NO:6.
7. A nucleic acid sequence pair encoding an interleukin-12 (IL-12) protein heterodimer, the nucleic acid sequence pair comprising an IL-12p35 nucleic acid sequence and an IL-12p40 nucleic acid sequence, wherein the IL-12p35 nucleic acid sequence has at least 80% sequence identity to SEQ ID NO:3, and the IL-12p40 nucleic acid sequence has at least 80% sequence identity to SEQ ID NO:6.
8. The nucleic acid sequence pair of claim 7 , wherein expression of the IL-12protein heterodimer from the nucleic acid sequence pair is increased by at least 2-fold in comparison to expression of the IL-12 protein heterodimer from a native mammalian IL-12 nucleic acid sequence pair.
9. The nucleic acid sequence pair of claim 7 , wherein the IL-12p35 nucleic acid sequence comprises at least 55% GC content and the IL-12p40 nucleic acid sequence comprises at least 55% GC content.
10. The nucleic acid sequence pair of claim 7 , wherein the IL-12p35 nucleic acid sequence has all potential splice sites removed and the IL-12p40 nucleic acid sequence has all potential splice sites removed.
11. The nucleic acid sequence pair of claim 7 , wherein the nucleic acid sequence encoding the IL-12p35 has at least 80% of the non-native codons of SEQ ID NO:3 (huIL12p35opt) identified in FIG. 6 , wherein the nucleic acid sequence encoding the IL-12p40 has at least 80% of the non-native codons of SEQ ID NO:6 (huIL12p40opt) identified in FIG. 8 .
12. The nucleic acid sequence pair of claim 11 , wherein the nucleic acid sequence encoding the IL-12p35 has non-native codons at one or more of codon numbers 2, 3, 6, 7, 8, 9, 11, 12, 15, 16, 19, 20, 21, 22, 23, 25, 26, 28, 29, 30, 32, 33, 36, 38, 41, 42, 46, 47, 48, 49, 52, 55, 56, 57, 58, 59, 60, 61, 63, 65, 66, 67, 69, 70, 71, 72, 73, 75, 76, 77, 78, 81, 84, 85, 86, 87, 88, 89, 90, 91, 93, 95, 97, 98, 99, 100, 102, 103, 105, 106, 107, 109, 112, 113, 114, 116, 117, 118, 121, 124, 125, 126, 127, 128, 129, 131, 140, 142, 143, 145, 148, 149, 151, 154, 155, 156, 157, 161, 162, 163, 164, 166, 169, 170, 171, 174, 176, 178, 179, 180, 181, 182, 183, 184, 185, 187, 188, 189, 190, 191, 192, 197, 198, 199, 200, 203, 204, 206, 208, 209, 210, 211, 214, 215, 217 and 219, wherein the codons are as identified in FIG. 6 , and wherein the nucleic acid sequence encoding the IL-12p40 has non-native codons at one or more of codon numbers 2, 6, 9, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 25, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 43, 44, 46, 48, 49, 50, 52, 53, 54, 55, 56, 57, 59, 61, 62, 65, 66, 69, 71, 73, 74, 75, 76, 78, 80, 82, 83, 84, 85, 89, 90, 92, 93, 96, 97, 99, 100, 102, 104, 106, 108, 109, 110, 111, 113, 114, 115, 116, 117, 121, 122, 123, 124, 125, 128, 129, 130, 133, 136, 137, 138, 139, 141, 145, 146, 147, 149, 150, 151, 152, 153, 155, 157, 158, 159, 160, 162, 163, 166, 169, 171, 172, 173, 174, 175, 176, 177, 179, 180, 181, 182, 187, 190, 191, 197, 198, 200, 201, 202, 205, 207, 208, 210, 212, 213, 214, 215, 218, 220, 221, 224, 225, 226, 230, 234, 235, 237, 238, 241, 245, 246, 248, 249, 252, 255, 259, 261, 263, 264, 265, 266, 267, 270, 272, 275, 276, 277, 281, 283, 284, 286, 287, 288, 289, 291, 294, 295, 296, 298, 301, 302, 303, 304, 305, 306, 307, 310, 313, 315, 316, 317, 318, 320, 321, 323, 324, 326 and 328, wherein the codons are as identified in FIG. 8 .
13. An expression vector comprising a nucleic acid sequence pair of claim 7 .
14. An isolated mammalian cell comprising a nucleic acid sequence pair of claim 7 .
15. An isolated mammalian cell comprising an expression vector of claim 13 .
16. A composition comprising the nucleic acid sequence pair of claim 7 , and a pharmaceutically acceptable excipient.
17. A method of expressing IL-12in a mammalian cell, the method comprising introducing a recombinant vector into a mammalian cell to express a nucleic acid sequence pair encoding an IL-12protein heterodimer, the nucleic acid sequence pair comprising an IL-12p35 nucleic acid sequence and an IL-12p40 nucleic acid sequence, wherein the IL 12p35 nucleic acid sequence has at least 80% sequence identity to SEQ ID NO:3, and the IL 12p40 nucleic acid sequence has at least 80% sequence identity to SEQ ID NO:6.
18. The method of claim 17 , wherein the nucleic acid sequence pair encoding the IL-12 protein heterodimer is expressed in vitro.